著者: BlierPierre, GommollCarl, ChenChangzheng, KramerKenneth

原題: Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials.

著者: WesnesKeith A, GommollCarl, ChenChangzheng, SambunarisAngelo, McIntyreRoger S, HarveyPhilip D

原題: Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study.

著者: ThaseMichael E, GommollCarl, ChenChangzheng, KramerKenneth, SambunarisAngelo

原題: Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.

著者: KornsteinSusan G, GommollCarl, ChenChangzheng, KramerKenneth

原題: The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD.

著者: FreemanMarlene P, FavaMaurizio, GommollCarl, ChenChangzheng, GreenbergWilliam M, RuthAdam

原題: Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.

著者: McIntyreRoger S, GommollCarl, ChenChangzheng, RuthAdam

原題: The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.

著者: ZadkaŁukasz, DziwotaEwelina, OlajossyMarcin

原題: LEVOMILNACIPRAN--A SUCCESSOR OF MILNACIPRAN WITH A HIGHER NORADRENERGIC SELECTIVITY.

著者: BrunoAntonio, MorabitoPaolo, SpinaEdoardo, MuscatelloMaria Rosaria

原題: The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.

著者: KöhlerStephan, CierpinskyKatharina, KronenbergGolo, AdliMazda

原題: The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.

著者: ChenLaishun, GreenbergWilliam M, GommollCarl, O'ConnorJoann, ZukinStephen R, PericlouAntonia, GhahramaniParviz

原題: Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.

著者: ChenLaishun, GreenbergWilliam M, Brand-SchieberElimor, WangsaJulie, PericlouAntonia, GhahramaniParviz

原題: Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.

著者: RomanMarian W, WilkinsonShannon M

原題: Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.

著者: ScottLesley J

原題: Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.

著者: DeardorffWilliam James, GrossbergGeorge T

原題: A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.

著者: JasiakNatalia M, BostwickJolene R

原題: Risk of QT/QTc prolongation among newer non-SSRI antidepressants.

著者: MontgomeryStuart A, GommollCarl P, ChenChangzheng, GreenbergWilliam M

原題: Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.

著者: SansoneRandy A, SansoneLori A

原題: Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison.

著者: ChenLaishun, BoinpallyRamesh, GreenbergWilliam M, WangsaJulie, PericlouAntonia, GhahramaniParviz

原題: Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants.

著者: SambunarisAngelo, GommollCarl, ChenChangzheng, GreenbergWilliam M

原題: Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.

著者: MagoRajnish, MahajanRajeev, ThaseMichael E

原題: Levomilnacipran: a newly approved drug for treatment of major depressive disorder.

著者: SaraceniMegan M, VenciJineane V, GandhiMona A

原題: Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.

著者: SambunarisAngelo, BoseAnjana, GommollCarl P, ChenChangzheng, GreenbergWilliam M, SheehanDavid V

原題: A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.

著者: MontgomeryStuart A, MansuyLucilla, RuthAdam C, LiDayong, GommollCarl

原題: The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.

著者: BakishDavid, BoseAnjana, GommollCarl, ChenChangzheng, NunezRene, GreenbergWilliam M, LiebowitzMichael, KhanArif

原題: Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.

著者: CitromeL

原題: Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

著者: HairPhilip, CameronFiona, Garnock-JonesKarly P

原題: Levomilnacipran extended release: first global approval.

著者: MagoRajnish, ForeroGiovanna, GreenbergWilliam M, GommollCarl, ChenChangzheng

原題: Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.

著者: MontgomeryStuart A, MansuyLucilla, RuthAdam, BoseAnjana, LiHua, LiDayong

原題: Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.

著者: AsnisGregory M, BoseAnjana, GommollCarl P, ChenChangzheng, GreenbergWilliam M

原題: Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.